La cadena de opciones muestra datos clave de las opciones de acciones de SpringWorks Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para SpringWorks Therapeutics..

SpringWorks Therapeutics (NASDAQ:SWTX) Bolsa, Cadena de Opciones

SpringWorks Therapeutics

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) with a Market Perform and lowers the price target from $40 to $38.

News

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Market Perform on BankUnited, Lowers Price Target to $38

WIIM

STEM

Stem shares are trading higher after the company reported better-than-expected Q1 financial results.

Wells Fargo analyst Ike Boruchow maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Equal-Weight and lowers the price target from $65 to $55.

URBN

Wells Fargo Maintains Equal-Weight on Urban Outfitters, Lowers Price Target to $55

INVO Fertility shares are trading higher after the company reported a year-over-year increase in Q4 financial results.

RBC Capital analyst Keith Mackey maintains NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) with a Outperform and lowers the price target from $20 to $19.

RBC Capital Maintains Outperform on NOV, Lowers Price Target to $19

<a href="https://www.youtube.com/watch?v=B-1xpqn6z2o" title="https://www.youtube.com/watch?v=B-1xpqn6z2o">https://www.youtube.com/watch?v=B-1xpqn6z2o</a>

Macro Economic Events

Politics

Global

Economics

General

President Trump Hosts Cabinet Meeting, Says At A Certain Point Hope For Deal With China; Fairness With China Includes IP

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Outperform and lowers the price target from $414 to $409.

Keefe, Bruyette & Woods Maintains Outperform on Aon, Lowers Price Target to $409

Market Summary

SNAP

Benzinga Market Summary: GDP Contracts In Q1, Snap Falls After Not Providing Q2 Guidance, US Dollar Index Rises, Gold Falls

ECARX Holdings shares are trading higher after the company reported a Q1 EPS beat.

American Water Works Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) has outperformed the market over the past 15 years by 2.56% on an annualized basis producing an average annual return of 13.68%. Currently, American Water Works Co has a market capitalization of $28.43 billion. 
Buying $1000 In AWK: If an investor had bought $1000 of AWK stock 15 years ago, it would be worth $6,649.70 today based on a price of $145.79 for AWK at the time of writing.
<h3>American Water Works Co's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746027912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In American Water Works Co 15 Years Ago Would Be Worth Today

GCL Global shares are trading higher after the company announced it will acquire Ban Leong Technologies for $0.4580 per share.

Garmin Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>)&nbsp;stock declined on Wednesday after it reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45095626/garmin-announces-first-quarter-2025-results" rel="noreferrer noopener">first-quarter 2025</a> results.
The company reported quarterly revenue growth of 11% year-on-year to $1.54 billion, beating the&nbsp;analyst consensus estimate of $1.50 billion.&nbsp;
The GPS navigation and wearable technology company's adjusted EPS of $1.61 missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate</a> of $1.67.&nbsp;
Segments: Revenue from Fitness grew by 12%&nbsp;year over year&nbsp;to $384.72 million, led by growth in advanced wearables. Outdoor revenue increased by 20%&nbsp;year over year&nbsp;to $438.5 million, primarily due to growth in adventure watches.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44876406/retail-slowdown-and-tariff-turbulence-hit-leisure-stocks-says-analyst" rel="noreferrer noopener">Retail Slowdown, Tariffs Jolt Leisure Stocks: Analyst Revises Estimates For Topgolf, Harley-Davidson And More</a>
Aviation revenue rose 3% year over year&nbsp;at $223.11 million,&nbsp;driven by the OEM product categories. Marine revenue decreased by 2%&nbsp;year over year&nbsp;to $319.44 million due to the timing of promotions that affected revenue across several product categories in the quarter. Auto OEM&nbsp;grew 31% year over year&nbsp;to $169.33 million, primarily driven by growth in domain controllers.
The gross margin decreased to 57.6%, down from 58.1% year over year. The&nbsp;operating margin was 21.7% compared to 21.6% a year ago.
Garmin generated $380.73 million in free cash flow for the quarter, compared to $402.14 million a year ago.&nbsp;As of March 29, 2025, it&nbsp;held $3.9 billion in cash and equivalents.
FY25 Outlook: Garmin&nbsp;now expects revenue of $6.85 billion (<a target="_blank" href="https://www.benzinga.com/25/02/43812509/garmin-q4-earnings-wearables-and-adventure-watches-drive-growth-raises-dividend-20-projects-68-billion-revenue-for-2025" rel="noreferrer noopener">up from prior</a> $6.80 billion) versus the&nbsp;analyst consensus estimate of $6.83 billion. It&nbsp;reiterated an adjusted EPS&nbsp;outlook of $7.80&nbsp;against the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate of $7.92</a>.&nbsp;
In its forward outlook, the company said, &#8220;The forward-looking financial measures in our 2025&nbsp;guidance include certain economic assumptions such as foreign currency exchange rates and tariffs which are fluid and can rapidly change favorably or unfavorably.&#8221;
Price Action: GRMN stock is down 7.39% at $189.02 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45067312/paypal-earnings-beat-but-slower-spending-and-checkout-use-weigh-on-results" target="_blank" rel="noreferrer noopener">PayPal Earnings Beat, But Slower Spending And Checkout Use Weigh On Results</a></li>
</ul>
Photo by Dontree_M via Shutterstock

Earnings

Guidance

Movers

Tech

GRMN

Garmin Lifts Sales Outlook, But Tightening Margin Sends Stock Sliding

Wells Fargo analyst Ike Boruchow maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Equal-Weight and lowers the price target from $7 to $4.

Wells Fargo Maintains Equal-Weight on Under Armour, Lowers Price Target to $4

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Alerus Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) with a Market Perform and raises the price target from $21 to $22.

ALRS

Keefe, Bruyette & Woods Maintains Market Perform on Alerus Financial, Raises Price Target to $22

<a href="https://www.airbus.com/en/investors/financial-results" title="https://www.airbus.com/en/investors/financial-results">https://www.airbus.com/en/investors/financial-results</a>

European Aeronautic Defence And Space Unsponsored

EADSY

Airbus Sees 2025 FCF Before Customer Financing Of Around €4.5 Billion; Sees 2025 Adj EBIT Of Around €7 Billion; Expects To Deliver About 820 Commercial Aircraft In 2025

Norwegian Cruise Line Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) shares plummeted Thursday after the company reported worse-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45094877/norwegian-cruise-line-holdings-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">first-quarter 2025 results</a>.
The company reported a first-quarter revenue decline of 2.9% year over year to $2.127 billion, missing the analyst consensus estimate of $2.14 billion.
This reflects a 2% drop in Capacity Days due to more berths for larger ships in dry dock and a strategic reduction in passenger air participation rates.
Passenger ticket revenues fell 2.8% YoY to $1.418 billion, and Onboard revenue declined 3.1% to $708.87 million. Total cruise operating expenses decreased 6% to $1.303 billion.
Adjusted EBITDA for the quarter stood at $453.07 million, down 2.3% YoY, and the margin gained 12 bps to 21.3%. Adjusted EPS of 7 cents below the consensus estimate of 9 cents.
Operating income fell 8% to $200.9 million, and the operating margin of 9.4% contracted 52 basis points.
The company's 12-month forward bookings softened but remained within the optimal range. Q1 2025 occupancy was 101.5%, down year-over-year due to dry-dock capacity. Advance ticket sales rose 2.6% to $3.9 billion.
Also Read: <a href="https://www.benzinga.com/25/04/44793931/norwegian-cruise-line-plans-major-upgrade-to-bahamian-island-retreat" target="_blank" rel="noreferrer noopener">Norwegian Cruise Line Plans Major Upgrade To Bahamian Island Retreat</a>
As of March 31, 2025, the company had a total debt of $14.0 billion and a Net Debt of $13.8 billion. Liquidity at quarter-end was $1.4 billion, including $184.4 million in cash and $1.0 billion available under the Revolving Loan Facility.
Operating cash flow for the quarter totaled $679.221 million, down 15.8% YoY.
Gross margin per Capacity Day rose 5% as reported and 7% in Constant Currency. Net Yield grew 0.6%, as reported, and 1.2% in Constant Currency, exceeding guidance.
Gross Cruise Costs per Capacity Day were $297, down from $300, while Adjusted Net Cruise Cost excluding Fuel increased 2.9%, better than the 3.9% guidance.
"Looking ahead, our proven track record of long-term Net Yield growth, strong cost control, continued record guest satisfaction scores and guest repeat rates give us confidence about our future. Thus, as we remain mindful of the evolving macroeconomic environment and despite recent volatility, we are maintaining our full year 2025 Adjusted EBITDA and Adjusted EPS guidance," said Harry Sommer, president and chief executive officer of Norwegian Cruise Line Holdings Ltd.
&#8220;While we recognize there may be potential pressures on the top line, we believe these can be effectively offset by the continued execution of our cost savings initiatives. Our focus remains on managing the business for the long term &#8211; balancing disciplined pricing and cost control with guest experience and strategic investments for the future,&#8221; Sommer added.
2025 Outlook: Norwegian Cruise Line expects FY25 net yield on a constant currency basis to increase 2.0%-3.0% and occupancy of 102.5%.
Reaffirmed Adjusted EBITDA guidance of $2.72 billion and adjusted EPS of $2.05, with a consensus of $2.07.
Q2 Outlook: Norwegian Cruise Line sees net Yield of 2.5%. Adjusted EPS of ~$0.51 versus an estimate of $0.51.
NCLH for the second quarter Occupancy is expected to be ~103.2%. Sees Adj. EBITDA of ~$670 million.
Price Action: NCLH shares are trading lower by 8.4% at $15.92 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45104438/starbucks-stock-tumbles-on-q2-earnings-ceo-says-progress-is-happening-below-the-surface">Starbucks Stock Tumbles On Q2 Earnings, CEO Says Progress Is Happening &#8216;Below The Surface&#8217;</a></li>
</ul>
Photo: Shutterstock

NCLH

Norwegian Cruise Line Tumbles After Earnings Miss, Still Confident In 2025 Guidance

Wells Fargo analyst Ike Boruchow maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Underweight and lowers the price target from $310 to $300.

ULTA

Wells Fargo Maintains Underweight on Ulta Beauty, Lowers Price Target to $300

RBC Capital analyst Nik Modi maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Outperform and raises the price target from $69 to $71.

MDLZ

RBC Capital Maintains Outperform on Mondelez International, Raises Price Target to $71

Airbus Q1 Revenue €13.5 Billion; Q1 EPS €1.01; Adjusted Free Cash Flow €-300 Million; 2025 Guidance Unchanged; Says As Basis For Its 2025 Guidance, Company Excludes Impact Of Tariffs On Its Business

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and raises the price target from $64 to $67.

INCY

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $67

Press Releases

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Health Care

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

Comments

SpringWorks Therapeutics

SpringWorks Therapeutics (SWTX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL